禾元生物科创板IPO注册生效 同日“稻米造血”药品获批上市

Core Insights - The China Securities Regulatory Commission has approved Wuhan Heyuan Biotechnology Co., Ltd. for its initial public offering (IPO) registration [1] - The National Medical Products Administration has granted priority review approval for Heyuan's recombinant human albumin injection (brand name: Aofumin), making it the first recombinant human serum albumin product approved for sale in China [1] - Heyuan Biotechnology aims to raise 2.4 billion yuan through its IPO, primarily for the construction of an industrialization base for recombinant human albumin, new drug research and development, and to supplement working capital [1] Company Overview - Heyuan Biotechnology, established in 2006, focuses on innovative drug research and development [1] - The company’s recombinant human albumin is derived from rice endosperm cell expression, a process referred to as "rice blood production" [1] Market Potential - The third-generation technology platform of Heyuan has achieved an expression level of 20 to 30 g/kg for rice human albumin, marking a significant technological breakthrough [2] - The company’s industrialization base is expected to produce 12 million vials of recombinant human serum albumin annually, with operations projected to commence in the second quarter of 2026 [2] - Heyuan anticipates a substantial market opportunity for its product HY1001, with projected sales revenues of 444 million yuan in 2026 and 1.567 billion yuan by 2030, addressing the current reliance on imports for human serum albumin in China [2]